Switch theme
Sign up to access all valuation multiples
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
2010
39
LTM Revenue n/a
LTM EBITDA n/a
$8.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
JFL Life Sciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, JFL Life Sciences achieved revenue of $5.4M and an EBITDA of $0.6M.
JFL Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See JFL Life Sciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.0M | $5.4M | XXX | XXX | XXX |
| Gross Profit | $0.9M | $1.0M | XXX | XXX | XXX |
| Gross Margin | 18% | 18% | XXX | XXX | XXX |
| EBITDA | $0.6M | $0.6M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 11% | XXX | XXX | XXX |
| Net Profit | $0.3M | $0.3M | XXX | XXX | XXX |
| Net Margin | 7% | 6% | XXX | XXX | XXX |
| Net Debt | $1.8M | $0.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, JFL Life Sciences's stock price is INR 20 (or $0).
JFL Life Sciences has current market cap of INR 662M (or $7.7M), and EV of INR 718M (or $8.3M).
See JFL Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.3M | $7.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, JFL Life Sciences has market cap of $7.7M and EV of $8.3M.
JFL Life Sciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate JFL Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for JFL Life Sciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $8.3M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 14.4x | XXX | XXX | XXX |
| P/E | 20.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 31.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJFL Life Sciences's NTM/LTM revenue growth is n/a
JFL Life Sciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $11K for the same period.
Over next 12 months, JFL Life Sciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate JFL Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for JFL Life Sciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $11K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 8% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
JFL Life Sciences acquired XXX companies to date.
Last acquisition by JFL Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . JFL Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was JFL Life Sciences founded? | JFL Life Sciences was founded in 2010. |
| Where is JFL Life Sciences headquartered? | JFL Life Sciences is headquartered in India. |
| How many employees does JFL Life Sciences have? | As of today, JFL Life Sciences has 39 employees. |
| Is JFL Life Sciences publicy listed? | Yes, JFL Life Sciences is a public company listed on NSE. |
| What is the stock symbol of JFL Life Sciences? | JFL Life Sciences trades under JFLLIFE ticker. |
| When did JFL Life Sciences go public? | JFL Life Sciences went public in 2022. |
| Who are competitors of JFL Life Sciences? | Similar companies to JFL Life Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of JFL Life Sciences? | JFL Life Sciences's current market cap is $7.7M |
| What is the current revenue growth of JFL Life Sciences? | JFL Life Sciences revenue growth between 2023 and 2024 was 9%. |
| Is JFL Life Sciences profitable? | Yes, JFL Life Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
